SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Term Catalysts
– Company advancing clinically proven platform therapy, the Selective Cytopheretic Device (SCD), to address the life-threatening consequences of hyperinflammation – SCD lead program in Acute Kidney Injury (AKI) with potential FDA approval for pediatric AKI …